Diacerein for osteoarthritis: An open-label comparative trial
https://doi.org/10.14412/1996-7012-2016-1-21-25
Abstract
Osteoarthritis (OA) is a degenerative joint disease that is accompanied by cartilage destruction, synovial membrane inflammatory changes, and subchondral bone remodeling.
Objective: to perform comparative evaluation of the efficiency of knee OA treatment with diacerein, hyaluronic acid, and nonsteroidal antiinflammatory drugs at short- and long-term follow-up.
Patients and methods. An open-label comparative enrolled 192 patients with knee arthritis: 68.5% women and 31.5% men (mean age, 52.7±1.79 years; mean disease duration, 7 years). The patients were divided into three groups matched for gender, age, and disease duration: Group 1 (n=63) took diacerein 100 mg/day; Group 2 (n=65) received intraarticular hyaluronic acid 2 ml thrice at an interval of 7 days; Group 3 (n=64) had diclofenac 75 mg/day. The patients of all the three groups had a similar magnitude of its symptoms and Kellgren grade. Magnetic resonance imaging (MRI) and arthroscopic examination of the knee joint were performed to assess the results of treatment in the patients.
Results. To evaluate the chondroprotective effect of the drugs, the authors used their proposed arthroscopic and MRI criteria (sensitivity, 89.7%; specificity, 93.1%) that allow abnormally changed and normal cartilages to be identified. At months 2 of treatment, all the three drugs ensured a considerable pain intensity reduction that persisted till 12 weeks. The important benefit of diacerein and hyaluronic acid was their aftereffect for further 3 months.
About the Authors
L. V. Luchikhina
City Clinical Hospital Thirty-One, Department of Propedeutics, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
42, Lobachevsky St., Moscow 119415
Russian Federation
42, Lobachevsky St., Moscow 119415
D. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Балабанова РМ. Остеоартроз или остеоартрит? Современное представление о болезни и ее лечении. Современная ревматология. 2013;7(3):67-70. [Balabanova RM. Osteoarthrosis or osteoarthritis? A current view of the disease and its treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(3):67-70. (In Russ.)]. DOI:10.14412/1996-7012-2013-276
2. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1-2):237-46.
3. Fahy N, Farrell E, Ritter T, et al. Immune modulation to improve tissue engineering outcomes for cartilage repair in the osteoarthritic joint. Tissue Eng Part B Rev. 2015 Feb;21(1):55-66. doi: 10.1089/ten.TEB. 2014.0098. Epub 2014 Aug 4.
4. Pavelka K, Bruyеre O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An OpinionBased Report from the ESCEO. Drugs Aging. 2016 Feb;33(2):75-85. doi: 10.1007/s40266-016-0347-4.
5. Hwa SY, Burkhardt D, Little C, Ghosh P. The effects of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol. 2001 Apr;28(4):825-34.
6. Permuy M, Guede D, Lopez-Pena M, et al. Effects of diacerein on cartilage and subchondral bone in early stages of osteoarthritis in a rabbit model. BMC Vet Res. 2015 Jul 2;11:143. doi: 10.1186/s12917-015-0458-x.
7. Permuy M, Guede D, Lopez-Pena M, et al. Comparison of various SYSADOA for the osteoarthritis treatment: an experimental study in rabbits. BMC Musculoskelet Disord. 2015 May 20;16:120. doi: 10.1186/s12891-015-0572-8.
8. Bartels EM, Bliddal H, Schоndorff PK, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a metaanalysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010 Mar;18(3):289-96. doi: 10.1016/j.joca.2009.10.006. Epub 2009 Oct 14.
9. Kongtharvonskul J, Anothaisintawee T, McEvoy M, et al. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. Eur J Med Res. 2015 Mar 13;20:24. doi: 10.1186/s40001-015-0115-7.
10. Заигрова НК. Оценка эффективности препарата артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23-5. [Zaigrova NK. Evaluation of the efficacy of Arthrocare for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23-5. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2013-2434
11. Балабанова РМ. Применение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный ДАДБДНДД). Современная ревматология. 2015;9(3):30-2. [Balabanova RM. Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author's own experience). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(3):30-2. (In Russ.)]. DOI:10.14412/1996-7012-2015-3-30-32
12. Fidelix TS, Macedo CR, Maxwell LJ, et al. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi: 10.1002/14651858.CD005117.pub3.
13. Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015 Mar;38(3): 245-52. doi: 10.1007/s40264-015-0266-z.
14. Каратеев АЕ. Достоинства и недостатки диацереина. Современная ревматология. 2014;8(4):90-5. [Karateev AE. Diacerein: Advantages and disadvantages. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):90-5. (In Russ.)]. DOI:10.14412/1996-7012-2014-4-90-95
15. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986 Aug;29(8):1039-49.
16. Лучихина ЛВ. Артроз – ранняя диагностика и патогенетическая терапия. Москва: Медицинская энциклопедия; 2001. 167 с. [Luchikhina LV. Artroz – rannyaya diagnostika i patogeneticheskaya terapiya [Arthritis – early diagnosis and pathogenetic therapy]. Moscow: Meditsinskaya entsiklopediya; 2001. 167 p.]
17. Лучихина ЛВ, Каратеев ДЕ. Новые подходы к ранней диагностике артроза и перспективы его патогенетической терапии. Современная ревматология. 2014;8(4):33-8. [Luchikhina LV, Karateev DE. New approaches to early diagnosis of arthrosis and prospects for its pathogenetic therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2014;8(4):33-8. (In Russ.)]. DOI: http://dx.doi.org/10.14412/1996-7012-2014-4-33-38
Review
For citations:
Luchikhina LV, Karateev DE. Diacerein for osteoarthritis: An open-label comparative trial. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2016;10(1):21-25. (In Russ.) https://doi.org/10.14412/1996-7012-2016-1-21-25
Views:
2479
Email this article 